Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM); Plateforme de Protéomique Clinique de Montpellier (PPC); BioCampus (BCM); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM); Institut des Neurosciences de Montpellier (INM); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM); CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre Mémoire de Ressources et de Recherches (CMRR); Université de Montpellier (UM); Département de neurologie Montpellier; Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital Gui de Chauliac CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Université de Montpellier (UM); This work was funded, for its realization, by a grant from the “Union France Alzheimer.”
    • بيانات النشر:
      HAL CCSD
      BioMed Central
    • الموضوع:
      2023
    • Collection:
      Inserm: HAL (Institut national de la santé et de la recherche médicale)
    • نبذة مختصرة :
      International audience ; Background: Alzheimer’s disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived invasiveness are a limitation for large-scale implementation. Based on positive amyloid profiles, blood-based biomarkers should allow to detect people at risk for AD and to monitor patients under therapeutics strategies. Thanks to the recent development of innovative proteomic tools, the sensibility and specificity of blood biomarkers have been considerably improved. However, their diagnosis and prognosis relevance for daily clinical practice is still incomplete.Methods: The Plasmaboost study included 184 participants from the Montpellier’s hospital NeuroCognition Biobank with AD ( n = 73), mild cognitive impairments (MCI) ( n = 32), subjective cognitive impairments (SCI) ( n = 12), other neurodegenerative diseases (NDD) ( n = 31), and other neurological disorders (OND) ( n = 36). Dosage of β-amyloid biomarkers was performed on plasma samples using immunoprecipitation-mass spectrometry (IPMS) developed by Shimadzu (IPMS-Shim Aβ 42 , Aβ 40 , APP 669–711 ) and Simoa Human Neurology 3-PLEX A assay (Aβ 42 , Aβ 40 , t-tau). Links between those biomarkers and demographical and clinical data and CSF AD biomarkers were investigated. Performances of the two technologies to discriminate clinically or biologically based (using the AT(N) framework) diagnosis of AD were compared using receiver operating characteristic (ROC) analyses.Results: The amyloid IPMS-Shim composite biomarker (combining APP 669–711 /Aβ 42 and Aβ 40 /Aβ 42 ratios) discriminated AD from SCI (AUC: 0.91), OND (0.89), and NDD (0.81). The IPMS-Shim Aβ 42/40 ratio also discriminated AD from MCI (0.78). IPMS-Shim biomarkers have similar relevance to discriminate between amyloid-positive and amyloid-negative individuals (0.73 and 0.76 respectively) and ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/36800984; hal-04598384; https://hal.science/hal-04598384; https://hal.science/hal-04598384/document; https://hal.science/hal-04598384/file/s13195-023-01188-8.pdf; PUBMED: 36800984; PUBMEDCENTRAL: PMC9938625
    • الرقم المعرف:
      10.1186/s13195-023-01188-8
    • الدخول الالكتروني :
      https://hal.science/hal-04598384
      https://hal.science/hal-04598384/document
      https://hal.science/hal-04598384/file/s13195-023-01188-8.pdf
      https://doi.org/10.1186/s13195-023-01188-8
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.C49C3253